Nicotine restores olfactory function by activation of prok2R/Akt/FoxO3a axis in Parkinson’s disease
Background Olfactory dysfunction occurs frequently in Parkinson’s disease (PD). In this study, we aimed to explore the potential biomarkers and underlying molecular pathways of nicotine for the treatment of olfactory dysfunction in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced PD mice. Methods MPTP was introduced into C57BL/6 male mice to generate a PD model. Regarding in vivo experiments, we performed behavioral tests to estimate the protective effects of nicotine in MPTP-induced PD mice. RNA sequencing and traditional molecular methods were used to identify molecules, pathways, and biological processes in the olfactory bulb of PD mouse models. Then, in vitro experiments were conducted to evaluate whether nicotine can activate the prok2R/Akt/FoxO3a signaling pathway in both HEK293T cell lines and primary olfactory neurons treated with 1-methyl-4-phenylpyridinium ($ MPP^{+} $). Next, prok2R overexpression ($ prok2R^{+} $) and knockdown ($ prok2R^{−} $) were introduced with lentivirus, and the Akt/FoxO3a signaling pathway was further explored. Finally, the damaging effects of $ MPP^{+} $ were evaluated in prok2R overexpression ($ prok2R^{+} $) HEK293T cell lines. Results Nicotine intervention significantly alleviated olfactory and motor dysfunctions in mice with PD. The prok2R/Akt/FoxO3a signaling pathway was activated after nicotine treatment. Consequently, apoptosis of olfactory sensory neurons was significantly reduced. Furthermore, $ prok2R^{+} $ and $ prok2R^{−} $ HEK293T cell lines exhibited upregulation and downregulation of the Akt/FoxO3a signaling pathway, respectively. Additionally, $ prok2R^{+} $ HEK293T cells were resistant to $ MPP^{+} $-induced apoptosis. Conclusions This study showed the effectiveness and underlying mechanisms of nicotine in improving hyposmia in PD mice. These improvements were correlated with reduced apoptosis of olfactory sensory neurons via activated prok2R/Akt/FoxO3a axis. These results explained the potential protective functions of nicotine in PD patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 22(2024), 1 vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Qinglong [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Apoptosis |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12967-024-05171-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055503357 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055503357 | ||
| 003 | DE-627 | ||
| 005 | 20240413064713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-024-05171-1 |2 doi | |
| 035 | |a (DE-627)SPR055503357 | ||
| 035 | |a (SPR)s12967-024-05171-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Guo, Qinglong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nicotine restores olfactory function by activation of prok2R/Akt/FoxO3a axis in Parkinson’s disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Olfactory dysfunction occurs frequently in Parkinson’s disease (PD). In this study, we aimed to explore the potential biomarkers and underlying molecular pathways of nicotine for the treatment of olfactory dysfunction in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced PD mice. Methods MPTP was introduced into C57BL/6 male mice to generate a PD model. Regarding in vivo experiments, we performed behavioral tests to estimate the protective effects of nicotine in MPTP-induced PD mice. RNA sequencing and traditional molecular methods were used to identify molecules, pathways, and biological processes in the olfactory bulb of PD mouse models. Then, in vitro experiments were conducted to evaluate whether nicotine can activate the prok2R/Akt/FoxO3a signaling pathway in both HEK293T cell lines and primary olfactory neurons treated with 1-methyl-4-phenylpyridinium ($ MPP^{+} $). Next, prok2R overexpression ($ prok2R^{+} $) and knockdown ($ prok2R^{−} $) were introduced with lentivirus, and the Akt/FoxO3a signaling pathway was further explored. Finally, the damaging effects of $ MPP^{+} $ were evaluated in prok2R overexpression ($ prok2R^{+} $) HEK293T cell lines. Results Nicotine intervention significantly alleviated olfactory and motor dysfunctions in mice with PD. The prok2R/Akt/FoxO3a signaling pathway was activated after nicotine treatment. Consequently, apoptosis of olfactory sensory neurons was significantly reduced. Furthermore, $ prok2R^{+} $ and $ prok2R^{−} $ HEK293T cell lines exhibited upregulation and downregulation of the Akt/FoxO3a signaling pathway, respectively. Additionally, $ prok2R^{+} $ HEK293T cells were resistant to $ MPP^{+} $-induced apoptosis. Conclusions This study showed the effectiveness and underlying mechanisms of nicotine in improving hyposmia in PD mice. These improvements were correlated with reduced apoptosis of olfactory sensory neurons via activated prok2R/Akt/FoxO3a axis. These results explained the potential protective functions of nicotine in PD patients. | ||
| 650 | 4 | |a Parkinson’s disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nicotine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Olfactory bulb |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prok2R/Akt/FoxO3a signaling pathway |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Apoptosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Liangchen |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Liao |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xuefei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaohui |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Zhenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Hongwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d BioMed Central, 2003 |g 22(2024), 1 vom: 12. Apr. |w (DE-627)SPR028930886 |w (DE-600)2118570-0 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12967-024-05171-1 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 12 |c 04 | ||